Biodexa Pharmaceuticals (BDRX) EBIT Margin (2015 - 2021)

Biodexa Pharmaceuticals (BDRX) has 5 years of EBIT Margin data on file, last reported at 806.48% in Q4 2021.

• For the quarter ending Q4 2021, EBIT Margin rose 28719352.0% year-over-year to 806.48%; the trailing twelve-month figure through Dec 2021 stood at 7279.41% (down 77243.0% YoY), and the FY2023 full-year result was 2103.41%, down 82559.0% from the prior year.
• EBIT Margin advanced to 806.48% in Q4 2021, from 288000.0% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 806.48% in Q4 2021 to a low of 288000.0% in Q4 2020.
• A 3-year average of 130759.96% and a median of 117116.68% in 2019 frame the typical range for EBIT Margin.
• Across the five-year window, EBIT Margin sank 28307913 bps in 2020 and surged 28719352 bps in 2021, its largest moves.
• Tracing BDRX's EBIT Margin over 3 years: stood at 4920.87% in 2019, then plunged by 5753 bps to 288000.0% in 2020, then surged by 100 bps to 806.48% in 2021.
• Business Quant data shows BDRX's EBIT Margin at 806.48% in Q4 2021, 288000.0% in Q4 2020, and 229312.5% in Q3 2020.